DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

In addition, Eli Lilly announced earlier this month that it is paying $630m for South Korea-based biotech OliX Pharmaceuticals’ antisense RNAi oligonucleotide OLX75016 to treat MASH.

Eli Lilly (NYSE: LLY) stock defied today's market ... colitis and metabolic dysfunction-associated steatohepatitis (MASH). In an unrelated announcement, Lilly said it has cut the price for 2.5 ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Eli Lilly (LLY) has agreed to acquire Organovo Holdings ... has shown a significant reduction in liver fat in a Phase II study on MASH (metabolic dysfunction-associated steatohepatitis ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...